Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.16
CRL's Cash to Debt is ranked lower than
52% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. CRL: 0.16 )
CRL' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 0.16

Equity to Asset 0.36
CRL's Equity to Asset is ranked higher than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. CRL: 0.36 )
CRL' s 10-Year Equity to Asset Range
Min: -0.28   Max: 0.72
Current: 0.36

-0.28
0.72
Interest Coverage 7.22
CRL's Interest Coverage is ranked higher than
50% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. CRL: 7.22 )
CRL' s 10-Year Interest Coverage Range
Min: 1.6   Max: 83.91
Current: 7.22

1.6
83.91
F-Score: 7
Z-Score: 2.49
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.78
CRL's Operating margin (%) is ranked higher than
87% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. CRL: 12.78 )
CRL' s 10-Year Operating margin (%) Range
Min: -33.48   Max: 22.58
Current: 12.78

-33.48
22.58
Net-margin (%) 9.61
CRL's Net-margin (%) is ranked higher than
87% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. CRL: 9.61 )
CRL' s 10-Year Net-margin (%) Range
Min: -38.84   Max: 14.3
Current: 9.61

-38.84
14.3
ROE (%) 17.59
CRL's ROE (%) is ranked higher than
89% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. CRL: 17.59 )
CRL' s 10-Year ROE (%) Range
Min: -230.9   Max: 58.93
Current: 17.59

-230.9
58.93
ROA (%) 6.97
CRL's ROA (%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. CRL: 6.97 )
CRL' s 10-Year ROA (%) Range
Min: -21.02   Max: 10.68
Current: 6.97

-21.02
10.68
ROC (Joel Greenblatt) (%) 17.82
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. CRL: 17.82 )
CRL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.63   Max: 83.75
Current: 17.82

-50.63
83.75
Revenue Growth (%) 9.90
CRL's Revenue Growth (%) is ranked higher than
80% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. CRL: 9.90 )
CRL' s 10-Year Revenue Growth (%) Range
Min: -17.6   Max: 13.4
Current: 9.9

-17.6
13.4
» CRL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CRL Guru Trades in Q3 2013

Ken Fisher 52,400 sh (New)
Steven Cohen 23,076 sh (+169.17%)
Pioneer Investments 101,212 sh (+120.51%)
PRIMECAP Management 1,697,800 sh (+3.53%)
John Rogers 2,749,905 sh (+0.57%)
Robert Olstein 176,000 sh (unchged)
Westport Asset Management 155,000 sh (unchged)
RS Investment Management 696,761 sh (-1.13%)
Paul Tudor Jones 8,700 sh (-9.38%)
Joel Greenblatt 41,454 sh (-17.4%)
Jim Simons 906,209 sh (-23.48%)
David Dreman 187,877 sh (-74.82%)
» More
Q4 2013

CRL Guru Trades in Q4 2013

Steven Cohen 38,698 sh (+67.7%)
Pioneer Investments 131,209 sh (+29.64%)
David Dreman 212,072 sh (+12.88%)
Paul Tudor Jones 9,300 sh (+6.9%)
Ken Fisher 54,280 sh (+3.59%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,697,800 sh (unchged)
RS Investment Management 689,250 sh (-1.08%)
Robert Olstein 169,000 sh (-3.98%)
John Rogers 2,629,217 sh (-4.39%)
Jim Simons 666,709 sh (-26.43%)
Joel Greenblatt 21,759 sh (-47.51%)
» More
Q1 2014

CRL Guru Trades in Q1 2014

Ken Fisher 210,712 sh (+288.19%)
Paul Tudor Jones 16,761 sh (+80.23%)
Pioneer Investments 163,867 sh (+24.89%)
Jim Simons 801,418 sh (+20.21%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,697,800 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
RS Investment Management 647,325 sh (-6.08%)
John Rogers 2,009,262 sh (-23.58%)
David Dreman 152,159 sh (-28.25%)
Robert Olstein 81,000 sh (-52.07%)
» More
Q2 2014

CRL Guru Trades in Q2 2014

Joel Greenblatt 11,280 sh (New)
Ken Fisher 371,824 sh (+76.46%)
Robert Olstein 133,000 sh (+64.2%)
Paul Tudor Jones 18,094 sh (+7.95%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,696,800 sh (-0.06%)
John Rogers 1,950,657 sh (-2.92%)
RS Investment Management 615,915 sh (-4.85%)
Pioneer Investments 123,177 sh (-24.83%)
David Dreman 109,870 sh (-27.79%)
Jim Simons 333,109 sh (-58.44%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Olstein 2014-06-30 Add 64.2%0.38%$50.74 - $61.47 $ 62.5614%133000
David Dreman 2014-06-30 Reduce -27.79%0.2%$50.74 - $61.47 $ 62.5614%109870
Ken Fisher 2014-06-30 Add 76.46%0.02%$50.74 - $61.47 $ 62.5614%371824
Joel Greenblatt 2014-06-30 New Buy0.01%$50.74 - $61.47 $ 62.5614%11280
Robert Olstein 2014-03-31 Reduce -52.07%0.68%$52.88 - $62.01 $ 62.568%81000
John Rogers 2014-03-31 Reduce -23.58%0.4%$52.88 - $62.01 $ 62.568%2009262
David Dreman 2014-03-31 Reduce -28.25%0.24%$52.88 - $62.01 $ 62.568%152159
Joel Greenblatt 2014-03-31 Sold Out 0.03%$52.88 - $62.01 $ 62.568%0
Ken Fisher 2014-03-31 Add 288.19%0.02%$52.88 - $62.01 $ 62.568%210712
Joel Greenblatt 2013-12-31 Reduce -47.51%0.03%$44.67 - $53.36 $ 62.5624%21759
David Dreman 2013-09-30 Reduce -74.82%0.74%$41.84 - $48.15 $ 62.5636%187877
Ken Fisher 2013-09-30 New Buy0.01%$41.84 - $48.15 $ 62.5636%52400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc - Jul 22, 2014

Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately.

From John Rogers (Trades, Portfolio)' Ariel Fund Second Quarter 2014 Commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc
Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately. Read more...
John Rogers' Ariel Fund Second Quarter 2014 Commentary
Quarter Ended June 30, 2014 Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
CRL's P/E(ttm) is ranked higher than
80% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 25.60 )
CRL' s 10-Year P/E(ttm) Range
Min: 8.59   Max: 95.93
Current: 25.6

8.59
95.93
P/B 4.50
CRL's P/B is ranked higher than
55% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. CRL: 4.50 )
CRL' s 10-Year P/B Range
Min: 0.75   Max: 5.58
Current: 4.5

0.75
5.58
P/S 2.46
CRL's P/S is ranked higher than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. CRL: 2.46 )
CRL' s 10-Year P/S Range
Min: 1.12   Max: 3.91
Current: 2.46

1.12
3.91
PFCF 17.47
CRL's PFCF is ranked higher than
91% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 17.47 )
CRL' s 10-Year PFCF Range
Min: 8.48   Max: 907.57
Current: 17.47

8.48
907.57
EV-to-EBIT 23.05
CRL's EV-to-EBIT is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 23.05 )
CRL' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 72.4
Current: 23.05

7.3
72.4
Current Ratio 2.18
CRL's Current Ratio is ranked higher than
63% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. CRL: 2.18 )
CRL' s 10-Year Current Ratio Range
Min: 1.21   Max: 3.49
Current: 2.18

1.21
3.49
Quick Ratio 1.84
CRL's Quick Ratio is ranked higher than
63% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. CRL: 1.84 )
CRL' s 10-Year Quick Ratio Range
Min: 0.95   Max: 3.02
Current: 1.84

0.95
3.02

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.64
CRL's Price/Tangible Book is ranked lower than
55% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. CRL: 15.64 )
CRL' s 10-Year Price/Tangible Book Range
Min: 2.86   Max: 40.21
Current: 15.64

2.86
40.21
Price/DCF (Projected) 1.44
CRL's Price/DCF (Projected) is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 1.44 )
CRL' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 1.78
Current: 1.44

0.94
1.78
Price/Median PS Value 1.08
CRL's Price/Median PS Value is ranked higher than
77% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CRL: 1.08 )
CRL' s 10-Year Price/Median PS Value Range
Min: 0.54   Max: 1.81
Current: 1.08

0.54
1.81
Price/Graham Number 4.19
CRL's Price/Graham Number is ranked higher than
76% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 4.19 )
CRL' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 8.23
Current: 4.19

1.66
8.23
Earnings Yield (Greenblatt) 4.30
CRL's Earnings Yield (Greenblatt) is ranked higher than
57% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. CRL: 4.30 )
CRL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 13.7
Current: 4.3

1.4
13.7
Forward Rate of Return (Yacktman) 3.65
CRL's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. CRL: 3.65 )
CRL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 21.4
Current: 3.65

2.9
21.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RV6.Germany
Charles River Laboratories International Inc, a Delaware corporation was incorporated in 1994. In 2000, it completed its initial public offering. The Company is a global provider of solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. It currently has two reporting segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company has been supplying research models to the drug development industry since 1947. The RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection (EMD). It provides its rodent models to numerous customers, including most pharmaceutical companies, a range of biotechnology companies, many government agencies, and hospitals and academic institutions. Research Model Services capitalize on the technologies and relationships developed through its research model business, and address the need among pharmaceutical and biotechnology companies to outsource the non-core aspects of their drug discovery activities. These services include those which are related to maintenance and monitoring of research models, and those which are designed to implement efficacy screening protocols to improve the client's drug evaluation process. The Company also offers four other categories of products and services within RMS - Genetically Engineered Models and Services, Insourcing Solutions, Discovery Research Services and Research Animal Diagnostic Services. The Company is a supplier of SPF fertile chicken eggs and chickens. SPF chicken embryos are used by animal health companies as self-contained "bioreactors" for the manufacture of live viruses. The EMD business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. In 2012, the EMD business acquired Accugenix, a provider of cGMP- compliant contract microbial identification testing. The Company is a provider of preclinical services both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development It currently provides preclinical services at multiple facilities located in the United States, Canada and Europe. It competes in the marketplace on the basis of its therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. As the Company's business operates in a number of distinct operating environments and in a variety of locations worldwide, it is subject to numerous, and sometimes overlapping, regulatory environments.
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 
Ken Heebner Top Holdings: AAPL Is a Buy at $380 Jan 11 2012 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Aug 03 2010 

More From Other Websites
Charles River Laboratories Schedules Third-Quarter 2014 Earnings Release and Conference Call Oct 08 2014
Charles River (CRL) Stock: Moving Average Crossover Alert Sep 09 2014
Charles River Laboratories to Present at Morgan Stanley Global Healthcare Conference Sep 08 2014
iKang Healthcare Group, Inc. (KANG) Jumps: Stock Surges 10.1% Aug 26 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials Aug 15 2014
Jim Cramer's Top Stock Picks: TSLA TNET CRL Aug 13 2014
Jim Cramer's 'Mad Money' Recap: Stocks That Stand the Test of Time Aug 12 2014
Cramer: Is Charles River getting ready to run? Aug 12 2014
Charles River Laboratories (CRL) Jumps: Stock Moves 5% Higher Aug 08 2014
Charles River Beats on Q2 Earnings & Revenues, Outlook Upped Aug 07 2014
Charles River Laboratories International Inc Earnings Call scheduled for 9:00 am ET today Aug 07 2014
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Aug 07 2014
Charles River Laboratories Announces Second-Quarter 2014 Results from Continuing Operations Aug 06 2014
Q2 2014 Charles River Laboratories International, Inc. Earnings Release - After Market Close Aug 06 2014
Charles River Laboratories to Webcast Investor Meeting Jul 24 2014
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014
Charles River Laboratories Schedules Second-Quarter 2014 Earnings Release and Conference Call Jul 07 2014
Insider Trading Alert - FWLT, CRL And SAH Traded By Insiders Jun 05 2014
Charles River Laboratories to Present at Jefferies and William Blair Conferences Jun 02 2014
UPDATE: Morgan Stanley Reiterates On Charles River Laboratories Following CEO Conference Call May 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK